Michael Lars Sjöström

Banque Pictet & Cie constructs portfolios of investments in large companies with stable earnings, balanced by shorter-term positions in stocks that have been mispriced or have the potential for recovery for bonds and equities. The fixed-income component generally includes core holdings of investment-grade sovereign debt and corporate bonds, complemented by opportunistic investments in high-yield corporate bonds and local currency emerging-market debt. Their fund mandates are managed by the team responsible for discretionary portfolios of mutual funds, exchange-traded funds and other pooled vehicles, operating on the principle of open architecture, selecting best-in-class Pictet or external funds. The firm also offers special mandates, such as absolute return mandates.

Sectoral aims to achieve superior returns for their investors by concentrating on primary research of company fundamentals and in-depth due diligence on companies to assess their scientific, business, financial and ESG aspects. The firm offers four Healthcare strategies: Global Healthcare, Emerging Healthcare, Small & Mid-Cap Healthcare & Biotech. They employ a bottom-up investment approach that can be categorized as Growth at a Reasonable Price (GARP).

Functions as a College/University

Sectoral is a fundamentals-based, medium- to long-term, GARP-oriented manager which focuses on companies in the healthcare (Pharmaceuticals, Generics, Biotechs and Medtechs) sector. They aim to achieve superior returns for investors by concentrating on primary research. The firm conducts preliminary research and analysis, including literature and documentation, interaction with companies and with Sectoral's Advisory Network, to identify investment candidates. They then conduct forecasting and scenario analyses, testing a range of assumptions and success factors critical to the company's success. They subsequently generate realistic valuation ranges for potential investments and assess the impact of the investment on the overall risk/return profile of the portfolio. They believe that specific risk is the most important risk component and have developed and refined their investment process to mitigate it. Their analysts attempt to determine the fair value for investment candidates as well as 1-year and 3-year price targets. Depending on the development stage of the company, they utilize models such as discounted cash-flow models, EBITDA models, classical growth models (PE approach), enterprise value/sales and peer group analysis to determine the price targets. Sectoral makes recommendations based on the resulting fair value to the current market value of each investment candidate and constructs portfolios comprised of analysts' investment recommendations. Their CIO determines the weight of each industry based on the attractiveness of expected growth, profitability, historic valuation and relative valuation.

Operates a clinical-stage biopharmaceutical company that develops oncology drugs

Develops intravascular devices for calcified cardiovascular disease

Sectoral Asset Management invests in companies located in North America and Europe. The firm focuses on biotechnology, medtech and life sciences sectors. It provides financing for late stage capital requirements.

Manufactures and markets emerging medical devices

Develops and manufactures diagnostic tools transforming care for patients with brain injuries